Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Cirrhosis is a major cause of morbidity and mortality; however, there are no approved therapies except orthotopic liver transplantation. Preclinical studies showed that bone-marrow-derived macrophage injections reduce inflammation, resolve fibrosis and stimulate liver regeneration. In a multicenter, open-label, parallel-group, phase 2 randomized controlled trial ( ISRCTN10368050 ) in n = 51 adult patients with compensated cirrhosis and Model for End-Stage Liver Disease (MELD) score ≥10 and ≤17, we evaluated the efficacy of autologous monocyte-derived macrophage therapy ( n = 27) compared to standard medical care ( n = 24). The primary endpoint was the difference in baseline to day 90 change in MELD score (ΔMELD) between treatment and control groups (ΔΔMELD). Secondary endpoints included adverse clinical outcomes, non-invasive fibrosis biomarkers and health-related quality of life (HRQoL) at 90 d, 180 d and 360 d. The ΔΔMELD between day 0 and day 90 in the treatment group compared to controls was −0.87 (95% confidence interval: −1.79, 0.0; P = 0.06); therefore, the primary endpoint was not met. During 360-d follow-up, five of 24 participants in the control group developed a total of 10 severe adverse events, four of which were liver related, and three deaths (two liver related), whereas no liver-related severe adverse events or deaths occurred in the treatment group. Although no differences were observed in biomarkers or HRQoL, exploratory analysis showed anti-inflammatory serum cytokine profiles after macrophage infusion. This study reinforces the safety and potential efficacy of macrophage therapy in cirrhosis, supporting further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“recent clinical trials have provided evidence that the administration of autologous macrophage therapy for liver fibrosis is safe, although the nature of these trials precluded efficacy assessment (52, 53).”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [53]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as longer-term results showed that treated patients developed fewer liver-related adverse effects and improved survival compared to the control group, suggesting potential clinical benefits (180, 181).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [181]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A phase II trial reported that infusion of bone marrow–derived monocytes did not significantly improve liver function, although circulating pro-inflammatory cytokines were reduced (213).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [213]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, the treatment group showed good safety and an increase in serum anti-inflammatory cytokines (IL-10, IL-13) (75).”
From Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although preclinical results were encouraging, randomized clinical trials in cirrhotic patients have shown inconsistent benefits.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [213]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687 · cited 1×
“Hepatic decompensation represents a clear inflection point in the trajectory of CLD, with median survival dropping from over 12 years in patients with compensated cirrhosis to approximately 2 years for patients with decompensated cirrhosis 5 .”
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788 · cited 1×
“Successful etiological treatment, such as antiviral therapy or sustained alcohol abstinence, can induce substantial fibrosis regression in patients with cirrhosis 8 with potential improvement in portal hypertension 9,10 , liver function and even ‘recompensation’ of decompensated cirrhosis 11–13 .”
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 1×
“Macrophages have been shown to have a pivotal role in the regression of organ fibrosis 22–25 .”
Self-citationLiver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310 · cited 1×
“Cirrhosis is end-stage scarring (fibrosis) that can be caused by any form of chronic liver injury and is characterized by disruption of the normal liver architecture, organ dysfunction and high blood pressure in the portal vein and its branches (portal hypertension) 4 .”
Self-citationRamachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
Self-citationGlobal epidemiology of cirrhosis — aetiology, trends and predictions
Huang, D. Q., Terrault, N. A., Tacke, F., Gluud, L. L., Arrese, M., Bugianesi, E., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00759-2 · Cited by 839 · cited 1×
“Globally, in 2017, there were 10.6 million prevalent cases of decompensated cirrhosis and 112 million prevalent cases of compensated cirrhosis 2 .”
InfluentialBoulter, L., Govaere, O., Bird, T. G., Radulescu, S., Ramachandran, P., Pellicoro, A., Ridgway, R. A., Seo, S. S., Spee, B., Van Rooijen, N., et al. (2012) · Nature Medicine · doi:10.1038/nm.2667 · Cited by 747
Self-citationYounossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999) · Gut · doi:10.1136/gut.45.2.295 · Cited by 670
Cited by
Macrophages: Subtypes, Distribution, Polarization, Immunomodulatory Functions, and Therapeutics
Peng, M., Li, N., Wang, H., Li, Y., Liu, H., Luo, Y., Lang, B., Zhang, W., Li, S., Tian, L., et al. (2025) · MedComm · doi:10.1002/mco2.70304 · Cited by 122
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
“Restorative macrophages play a key role in degrading the extracellular matrix and restoring normal liver architecture via their high expression of matrix metalloproteinases [271 – 274].”
The spatial and temporal activation of macrophages during fibrosis
Behmoaras, J. V., Mulder, K., Ginhoux, F., & Petretto, E. G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01186-x · Cited by 86
“Also, a recent report highlighted the potential value of autologous monocyte-derived macrophage therapy for cirrhosis 209 , which is supported by preclinical studies in mice 210 .”
Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease
Li, Z., Luo, G., Gan, C., Zhang, H., Li, L., Zhang, X., Xing, X., Hu, S., Tan, X., Ding, J., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02407-8 · Cited by 89
“These findings highlight the therapeutic potential of manipulating LAM phenotypes and abundance either through molecular drug interventions or direct injections of bone marrow-derived macrophages 52 .”
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
“42,43 In preclinical models, cell therapy with alternatively activated macrophages resolved necrosis following acute liver injury, and even ameliorated fi brosis.”
Metadata
- Authors
- Brennan, P. N., MacMillan, M., Manship, T., Moroni, F., Glover, A., Troland, D., MacPherson, I., Graham, C., Aird, R., Semple, S. I. K., Morris, D. M., Fraser, A. R., Pass, C., McGowan, N. W. A., Turner, M. L., Manson, L., Lachlan, N. J., Dillon, J. F., Kilpatrick, A. M., Campbell, J. D. M., Fallowfield, J. A., & Forbes, S. J.
- Affiliations
- University of Dundee (GB)
- MRC Centre for Regenerative Medicine (GB)
- Edinburgh Royal Infirmary (GB)
- Aberdeen Royal Infirmary (GB)
- Scottish National Blood Transfusion Service (GB)
- University of Edinburgh (GB)
- Glasgow Royal Infirmary (GB)
- Centre for Inflammation Research (GB)
- Corresponding author
- Forbes, Stuart J.
- ORCID
- Venue
- Nature Medicine
- Published
- 2025-01-10
- Volume
- 31
- Issue
- 3
- Pages
- 979-987
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11922741
- OpenAlex
- W4406231919
- Cited by
- 66
- References
- 51
- Citations by year
- 2026: 35 · 2025: 31
- FWCI
- 37.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, cc-by)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- RCUK | Medical Research Council (MR/M007588/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- liver cirrhosis, monocyte-derived macrophages, bone marrow-derived macrophages, MELD score, liver fibrosis, liver regeneration, anti-inflammatory cytokines, health-related quality of life, adverse events, compensated cirrhosis
- MeSH terms
- Adult, Aged, Female, Humans, Liver Cirrhosis, Macrophages, Male, Middle Aged, Quality of Life, Transplantation, Autologous, Biomarkers, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial. https://app.cochat.ai/papers/10.1038/s41591-024-03406-8
- The paper
- Brennan, P. N., MacMillan, M., Manship, T., Moroni, F., Glover, A., Troland, D., MacPherson, I., Graham, C., Aird, R., Semple, S. I. K., Morris, D. M., Fraser, A. R., Pass, C., McGowan, N. W. A., Turner, M. L., Manson, L., Lachlan, N. J., Dillon, J. F., Kilpatrick, A. M., . . . Forbes, S. J. (2025). Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03406-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.